Abstract Claims Description Full Text

Abstract

A method of therapeutically administering certain BZ1 specific trifluorobenzodiazepines in order to maximize the BZ1 effects and minimize the BZ2 effects on the human central nervous system in order to maximize the anti-anxiety, anticonvulsant and hypnotic effects and minimize the ataxic and incoordination effects of the drug. Also, a method of sublingual administration of trifluorobenzodiazepines and certain other compounds, such as propoxyphene and nefazodone, in order to decrease unwanted metabolites.

Other References

• Zohar et al., "Serotonergic Responsivity in Obsessive-Compulsive Disorder", Arch Gen Psychiatry, vol. 44, pp. 946-951 (Nov. 1987)
• Kahn et al., "Behavioral Indications for Serotonin Receptor Hypersensitivity in Panic Disorder", Psychiatry Research, vol. 25, pp. 101-104 (1988)
• Hollander et al., "Serotonergic and Noradrenergic Sensitivity in Obsessive-Compulsive Disorder: Behavioral Findings", American Journal of Psychiatry, vol. 145:8, pp. 1015-1017 (Aug. 1988)
• Walsh et al., "Neuroendocrine and Temperature Effects of Nefazodone in Healthy Volunteers", Biological Psychiatry, vol. 33, pp. 115-119 (1993)
• Shukla et al., "Pharmacokinetics, Absolute Bioavailability, and Disposition of ¹⁴ C! Nefazodone in the Dog", Drug Metabolism and Disposition, vol. 21, No. 3, pp. 502-507 (1993)
• Shukla et al., "Pharmacokinetics of Nefazodone Following Multiple Escalating Oral Doses in the Dog", European Journal of Drug Metabolism and Pharamcokinetics, vol. 17, No. 4, pp. 309-318 (1992